<DOC>
	<DOCNO>NCT01430351</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose temozolomide combination memantine , mefloquine , and/or metformin give patient glioblastoma already give radiation chemotherapy combination . The safety drug combination also study . Temozolomide design kill cancer cell damage DNA ( genetic material cell ) . The damage DNA may cause tumor cell death . Memantine design block activity protein find surface cell may control tumor growth survival . This may stop spread tumor cell . Mefloquine design block protein help clean waste cell destabilize cell membrane . Blocking protein may cause tumor cell death . Metformin design block protein tumor cell important tumor growth blood vessel development . This may cause cell death reduce spread disease .</brief_summary>
	<brief_title>Phase I Factorial Trial Temozolomide , Memantine , Mefloquine , Metformin Post-Radiation Therapy ( RT ) Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study group base join study . Three ( 3 ) 6 participant enrol group . - If Group 1 , take temozolomide memantine . - If Group 2 , take temozolomide mefloquine . - If Group 3 , take temozolomide metformin . If intolerable side effect see Groups 1-3 , next participant enrol Groups 4-6 . You also enrol study group base join study . - If Group 4 , take temozolomide , memantine , mefloquine . - If Group 5 , take temozolomide , memantine , metformin . - If Group 6 , take temozolomide , mefloquine , metformin . If intolerable side effect see Groups 4-6 , next 12 participant enrol Group 7 . If Group 7 , take temozolomide , memantine , mefloquine , metformin . The study drug dos may vary group group . The study doctor discus . Study Drug Administration : Each cycle 28 day . Unless side effect , receive dose level drug entire study . If side effect , dose dos receive later study group may lower . You take temozolomide mouth 1 time day Days 1-5 every cycle . You swallow temozolomide capsule whole , one right , without chew . They take empty stomach ( least 2 hour 1 hour eat ) 1 cup ( 8 ounce ) water . If Groups 1 , 4 , 5 , 7 , take memantine mouth 2 time day study . It take 12 hour apart . You swallow memantine capsule whole , one right , without chew . They take empty stomach ( least 2 hour 1 hour eat ) 1 cup water . If Groups 2 , 4 , 6 , 7 , take mefloquine mouth 1 time day Days 1-3 first week , Monday , Wednesday , Friday every week study . You take mefloquine food 1 cup water . If Groups 3 , 5 , 6 , 7 , take metformin mouth 2 time day every day study . It take 12 hour apart . You swallow metformin tablet whole , one right , without chew . They take food 1 cup water . While take multiple study drug , take mefloquine metformin together . You take temozolomide memantine together . You take mefloquine and/or metformin 2-4 hour apart temozolomide and/or memantine . If vomit take study drug , make dose take next schedule dose . Study Visits : Every week first cycle , every 4 week , ask drug may take side effect . Every week Cycle 1 , every 2 week , blood ( 1-2 teaspoon ) draw routine test . Every 4 week Cycles 1 2 , every 8 week : - You physical exam , include measurement vital sign . - You neurologic exam . - Your performance status record . Every 8 week : -You MRI scan CT scan brain check status disease . If Groups 2 , 4 , 6 , 7 , Day 1 Cycles 3 7 , ECG . At time study , extra test may perform doctor think need safety . The study doctor tell extra test . Length Study : You may take study drug 24 cycle , long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Long-Term Follow-Up : After stop taking study drug , study staff call every 3 month check . Each phone call take 5 minute . This investigational study . Each study drug FDA approve commercially available different us : - Temozolomide treatment type brain cancer - Memantine treatment Alzheimer 's disease - Mefloquine treatment malaria - Metformin treatment diabetes The use drug combination investigational . Up 144 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>1 . Patients histologically prove supratentorial glioblastoma gliosarcoma ( WHO grade IV astrocytoma ) eligible protocol . Patients eligible original histology lowgrade glioma subsequent histological diagnosis glioblastoma gliosarcoma make prior definitive treatment ( radiotherapy , chemotherapy ) . 2 . All patient must sign informed consent indicate aware investigational nature study . Patients must register prior treatment study drug . 3 . Patients must &gt; /= 18 year old . 4 . Patients must Karnofsky performance status ( KPS ) &gt; /= 60 . 5 . Patients must adequate bone marrow function ( WBC &gt; /= 3,000/Âµl , ANC &gt; /= 1,500/mm^3 , platelet count &gt; /= 100,000/mm^3 , hemoglobin &gt; /= 10 gm/dl ) , adequate liver function ( SGOT bilirubin &lt; 2 time ULN ) , adequate renal function ( creatinine &lt; 1.5 mg/dL ) start therapy . These test must perform within 14 day prior registration . Eligibility level hemoglobin may reach transfusion . 6 . For patient Mefloquine arm , baseline EKG without evidence prolong QTc interval &gt; 450 m clinically significant arrhythmia must obtain within 14 day prior registration . 7 . A brain scan perform within 14 day prior registration steroid dose stable decrease least 5 day . If steroid dose increase date image registration new baseline MR/CT require . The type scan , i.e. , MRI CT must use throughout period protocol treatment tumor measurement . 8 . Patients must complete standard radiation therapy concurrent TMZ must evidence progressive disease post treatment imaging . 9 . Women childbearing potential must negative serum urine BHCG pregnancy test document within 72 hour start therapy . 10 . Patients must register study within 5 week completion concurrent chemoradiation . 1 . Patients must significant medical illness investigator 's opinion adequately control appropriate therapy would compromise patient 's ability tolerate therapy . 2 . For Mefloquine arm , patient evidence QTc interval &gt; 450 m clinically significant arrhythmia baseline EKG obtain within 14 day registration ineligible protocol enrollment . 3 . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission therapy disease minimum 3 year , ineligible . 4 . Patients must active infection serious intercurrent medical illness . 5 . Patients must pregnant/breast feeding must agree practice adequate contraception ( Acceptable form birth control include condom spermicide and/or diaphragm spermicide , nonbarrier contraception tubal ligation , vasectomy , oral contraceptive , implant levonorgestrel , vaginal hormonal contraceptive ring ) . Patients must pregnant animal study show TMZ MFLOQ teratogenic , insufficient information estimate risk . 6 . Patients must disease obscure toxicity dangerously alter drug metabolism . Patients history psychosis/schizophrenia cardiac disease require betablocker treatment ( unable change medication nonbeta blocker ) , antimalarial drug , quinine quinidine eligible enrollment mefloquine contain arm . Patients active treatment one study drug time evaluation eligible enrollment arm containing study drug . 7 . For Mefloquine arm , patient must enzyme induce anticonvulsant ( EIAED ) ; treat physician elect change medication nonenzyme induce agent , 2weeks wash period require stopping EIAED prior initiation treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Brain cancer</keyword>
	<keyword>Central nervous system</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>GBM</keyword>
	<keyword>Post Radiation Therapy</keyword>
	<keyword>Post-RT</keyword>
	<keyword>External beam radiotherapy</keyword>
	<keyword>XRT</keyword>
	<keyword>Supratentorial glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Grade IV astrocytoma</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>Memantine</keyword>
	<keyword>Namenda</keyword>
	<keyword>Mefloquine</keyword>
	<keyword>Apo-Mefloquine</keyword>
	<keyword>Lariam</keyword>
	<keyword>Metformin</keyword>
</DOC>